Tianjin Hualida Biotechnology

Tianjin Hualida Biotechnology is a prominent Chinese biopharmaceutical company specializing in the development and large-scale manufacture of recombinant protein therapeutics and vaccines. Established in 1992 and based in the Tianjin Economic-Technological Development Area (TEDA), the company is a key subsidiary of the Tianjin Pharmaceutical Group. Its flagship product line, marketed under the brand name Anferon, consists of Recombinant Human Interferon alpha-2b in various formulations used to treat viral infections and oncological conditions. Hualida operates advanced GMP-certified facilities and has expanded its portfolio to include influenza vaccines and other biological products. The company plays a significant role in the domestic supply of essential biologics within the Chinese healthcare market.